Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates.
imaging
prostate cancer
prostate-specific membrane antigen (PSMA)
radical prostatectomy
staging
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
06 Mar 2022
06 Mar 2022
Historique:
received:
01
01
2022
revised:
26
02
2022
accepted:
02
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Purpose: to evaluate a unique subpopulation of radical prostatectomy (RP) candidates with “negative” prostate 68Ga-labeled prostate-specific membrane antigen (PSMA) positron emission tomography (PET) computed tomography (CT) imaging scans and to characterize the clinical implications of misleading findings. Materials and Methods: This case-control retrospective study compared the final histological outcomes of patients with “negative” pre-RP PSMA PET/CT prostate scans (with a prostate maximal standardized uptake value [SUVmax] below the physiologic uptake) to those with an “intense” prostatic tracer uptake (with a SUVmax above the physiologic uptake). The patients underwent an RP between March 2015 and July 2019 in five academic centers. Data on the demographics, comorbidities, prostate-specific antigen (PSA) and rectal exam findings, prior biopsies, imaging results, biopsies, and RP histology results were collected. Results: Ninety-seven of the 392 patients who underwent an RP had PSMA PET/CT imaging preoperatively. Fifty-two (54%) had a “negative” uptake (in the study group), and 45 (46%) had a “positive” uptake (in the control group). Only the lesion size and SUVmax values on the PSMA PET/CT differed between the groups preoperatively. On the histological analysis, only the ISUP score, seminal vesicles invasion, T stage, and positive margin rates differed between the groups (p < 0.05), while 50 (96%) study group patients harbored clinically significant disease (ISUP ≥ 2), with an extra-prostatic disease in 24 (46%), perineural invasion in 35 (67%), and positive lymph nodes in 4 (8%). Conclusions: Disease aggressiveness generally correlated with an intense PSMA uptake on the preoperative PSMA PET/CT, but a subpopulation of patients with clinically significant cancer and aggressive characteristics showed a deceptively weak PSMA uptake. These data raise a concern about the unqualified application of PSMA PET/CT for staging RP candidates.
Identifiants
pubmed: 35330410
pii: jpm12030410
doi: 10.3390/jpm12030410
pmc: PMC8951096
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Mol Metab. 2018 Feb;8:158-166
pubmed: 29249638
J Nucl Med. 2018 Feb;59(2):238-243
pubmed: 28775203
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):235-242
pubmed: 29075832
Cancer Imaging. 2015 Mar 03;15:2
pubmed: 25889163
J Nucl Med. 2019 Mar;60(3):362-368
pubmed: 30042163
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4042-4053
pubmed: 34386839
EJNMMI Res. 2019 Feb 8;9(1):15
pubmed: 30737563
Clin Cancer Res. 2018 Dec 15;24(24):6300-6307
pubmed: 30139879
Eur J Radiol. 2021 Mar;136:109556
pubmed: 33485127
Endocr Relat Cancer. 2018 Oct 1;26(2):131-146
pubmed: 30400059
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
J Nucl Med. 2016 Nov;57(11):1720-1725
pubmed: 27261520
Insights Imaging. 2011 Dec;2(6):679-698
pubmed: 22347986
Radiographics. 2018 Jan-Feb;38(1):200-217
pubmed: 29320333
Medicine (Baltimore). 2014 Nov;93(26):e254
pubmed: 25474437
Prostate Cancer Prostatic Dis. 2021 Jun;24(2):423-430
pubmed: 32999466
Eur Urol. 2016 Oct;70(4):553-557
pubmed: 26810345
Eur Urol. 2018 May;73(5):656-661
pubmed: 29358059
Curr Radiopharm. 2018;11(1):4-13
pubmed: 29090673
Abdom Radiol (NY). 2020 Dec;45(12):4194-4201
pubmed: 32671440
Eur Urol. 2019 Oct;76(4):469-478
pubmed: 31345636
Nat Rev Urol. 2021 Feb;18(2):79-92
pubmed: 33328650
World J Urol. 2018 Apr;36(4):519-527
pubmed: 29344682
EJNMMI Res. 2020 Nov 10;10(1):138
pubmed: 33169183
Eur Urol. 2016 Dec;70(6):926-937
pubmed: 27363387
BJU Int. 2017 Feb;119(2):209-215
pubmed: 27207581
AJR Am J Roentgenol. 2004 May;182(5):1129-32
pubmed: 15100107
EJNMMI Res. 2022 Feb 11;12(1):10
pubmed: 35147810
Nucl Med Commun. 2019 Jan;40(1):86-91
pubmed: 30395048
J Nucl Med. 2010 Jul;51(7):1015-20
pubmed: 20554733
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):941-949
pubmed: 28138747